The startup operates a biotechnology platform that utilizes a proprietary ionic compound to develop oral and parenteral treatments for diseases characterized by neuronal degeneration due to inflammation. This platform supports preclinical development for multiple pathologies linked to acute and chronic inflammation, offering patients more effective and better-tolerated therapeutic alternatives.
Funding
Funding not disclosed
Founders
Product
Problem
In critical care scenarios such as septic shock, stroke, heart attack, and organ transplantation, ischemia/reperfusion injuries—tissue damage caused when blood supply returns after a period of oxygen deprivation—lead to significant complications, long-term organ dysfunction, and high mortality rates. Current treatments offer limited efficacy in preventing or mitigating these injuries.
Solution
YNIOS Pharma is developing injectable treatments based on its proprietary TA64 compound, designed to preserve organ function by supporting vascular integrity and modulating the immune response during ischemia/reperfusion events. TA64 aims to restore the natural ability of cells to modulate their innate immune capacity and produce a proportional physiological response to inflammatory aggression. By restoring cellular homeostasis, TA64 protects healthy cells and tissues from damage caused by excessive cytosolic and mitochondrial calcium, a key factor in cellular destruction and organ failure. The company is initially focusing on septic shock, followed by applications in solid organ transplantation, with a strategy to personalize treatment based on patient-specific biomarkers.
Target Audience
The primary target audience includes hospitals, intensive care units, and transplant centers seeking to improve outcomes for patients at risk of ischemia/reperfusion injuries during critical care procedures.
Features
- TA64 compound designed to restore cells' innate immune capacity.
- Injectable formulation for intravenous administration in critical care settings.
- Mechanism of action focused on modulating the immune response and preserving vascular integrity.
- Targeted approach to restore cellular homeostasis and prevent tissue damage from ischemia/reperfusion.
- Development program focused on identifying biomarkers for personalized treatment strategies.